Brief: Aadi Bioscience Reports Interim Results From Precision1 Trial Of NAB-Sirolimus

Whitehawk Therapeutics

14/12/2023 21:13

Dec 14 (Reuters) - Aadi Bioscience Inc  AADI.O :
    * AADI BIOSCIENCE REPORTS INTERIM RESULTS FROM PRECISION1
TRIAL OF
NAB-SIROLIMUS DEMONSTRATING ANTI-TUMOR ACTIVITY IN SOLID TUMORS
WITH TSC1 OR TSC2 INACTIVATING ALTERATIONS
    * AADI BIOSCIENCE INC - STUDY ON TRACK FOR COMPLETION BY END
2024;
FINAL DATA READOUT EXPECTED IN EARLY 2025
    * AADI BIOSCIENCE INC - 80 PATIENTS NOW ENROLLED IN
PRECISION1
SUPPORTING TWO-THIRDS INTERIM ANALYSIS EXPECTED IN 3Q 2024

Source text for Eikon:  ID:nPn13Y8SYa 
Further company coverage:  AADI.O 

 ((Reuters.Briefs@thomsonreuters.com;))